https://orcid.org/0000-0002-2961-8774
References
- Begley, C. G. (2013), “Six Red Flags for Suspect Work,” Nature, 497, 433–434. DOI: 10.1038/497433a.
- Begley, C. G., and Ellis, L. (2012), “Drug Development: Raise Standards for Preclinical Research,” Nature, 483, 531–533. DOI: 10.1038/483531a.
- Booth, B. (2011), “Academic Bias & Biotech Failures,” available at http://lifescivc.com/2011/03/academic-bias-biotech-failures/.
- EMA (2016), “Guidelines on Multiplicity Issues in Clinical Trials,” available at https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf.
- FDA (2017), “Multiple Endpoints in Clinical Trials: Guidance for Industry,” available at https://www.fda.gov/media/102657/download.
- Freedman, L. P., Cockburn, I. M., and Simcoe, T. S. (2015), “The Economics of Reproducibility in Preclinical Research,” PLoS Biology, 13, e1002165. DOI: 10.1371/journal.pbio.1002165.
- Gibson, E. W. (2020), “The Role of p-Values in Judging Strength of Evidence and Realistic Replication Expectations,” Statistics in Biopharmaceutical Research, 13. DOI: 10.1080/19466315.2020.1724560.
- Harrington, D., D’Agostino, R. B., Sr., Gatsonis, C., Hogan, J. W., Hunter, D. J., Normand, S. T., Drazen, J. M., and Hamel, M. B. (2019), “New Guidelines for Statistical Reporting in the Journal,” New England Journal of Medicine, 381, 285–286. DOI: 10.1056/NEJMe1906559.
- Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., Sharma, D., Thiyagarajan, B., on behalf of the ELITE II Investigators (2000), “Effects of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomized Trial—The Losartan Heart Failure Survival Trial Study ELITE II,” Lancet, 355, 1582–1587. DOI: 10.1016/S0140-6736(00)02213-3.
- Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Crowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., Chang, P. I., on behalf of ELITE Study Investigators (1997), “Randomized Trial of Losartan Versus Captopril in Patients Over 65 With Heart Failure (Evaluation of Losartan in the Elderly Study, ELITE),” Lancet, 349, 747–752. DOI: 10.1016/S0140-6736(97)01187-2.
- Prinz, F., Schlange, T., and Asadullah, K. (2011), “Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?,” Nature Reviews Drug Discovery, 10, 712,DOI: 10.1038/nrd3439-c1.
- Ruberg, S. J., Harrell, F. E., Jr., Gamalo-Siebers, M., LaVange, L., Lee, J. J., Price, K., and Peck, C. (2019), “Inference and Decision Making for 21st-Century Drug Development and Approval,” The American Statistician, 73, 319–327. DOI: 10.1080/00031305.2019.1566091.
- Wasserstein, R. L., Schirm, A. L., and Lazar, N. A. (2019), “Moving to a World Beyond p < 0.05,” The American Statistician, 73, 1–19.